Sugi Predict

Sugi Predict / Compounds / SCHEMBL1922467

SCHEMBL1922467

SCHEMBL1922467

Cc1cc(C)n(-c2c(C)nn3c(-c4ccc(Cl)cc4Cl)c(C)oc23)n1

nearest known ligand 0.42

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ DPP4 P27487 7/20 0.42
▸ THRB P10828 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ CRHR1 P34998 7/20 0.39
▸ DPP8 Q6V1X1 2/20 0.38
▸ LMNA P02545 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ CYP2C9 P11712 2/20 0.36
▸ CYP2C19 P33261 2/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ DPP9 Q86TI2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1922556 0.87 DPP4 (0.40) DPP4THRBNPC1CRHR1DPP8
SCHEMBL2256801 0.86 DPP4 (0.39) DPP4NPC1CRHR1DPP8CYP2C9
SCHEMBL1922662 0.86 DPP4 (0.41) DPP4NPC1CRHR1DPP8CYP2C9
SCHEMBL2258055 0.86 PTGS1 (0.39) DPP4CRHR1DPP8TSHRHSD17B10
SCHEMBL1922397 0.86 CRHR1 (0.37) DPP4CRHR1DPP8CYP2C9CYP2C19
SCHEMBL1923091 0.85 DPP4 (0.39) DPP4NPC1CRHR1DPP8LMNA
SCHEMBL1922525 0.83 DPP4 (0.44) DPP4CRHR1DPP8
SCHEMBL1922972 0.83 KDM4E (0.38) DPP4NPC1CRHR1KMT2A
SCHEMBL1922758 0.81 MAPT (0.42) DPP4NPC1CRHR1DPP8LMNA
SCHEMBL1922037 0.81 DPP4 (0.45) DPP4NPC1DPP8LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7994203-B2 Organic compounds NOVARTIS AG (CH) 2011-08-09 — — US claimed
US-20100035874-A1 Organic compounds NOVARTIS AG (CH) 2010-02-11 — — US claimed
US-7994203-B2 Organic compounds NOVARTIS AG (CH) 2011-08-09 — — US disclosed
US-7994203-B2 Organic compounds NOVARTIS AG (CH) 2011-08-09 — — US disclosed
US-7994203-B2 Organic compounds NOVARTIS AG (CH) 2011-08-09 — — US disclosed
EP-2328902-A1 PYRAZOLO [5,1-B]OXAZOLE DERIVATIVES AS CRF1 ANTAGONISTS Novartis AG (CH) 2011-06-08 — — EP disclosed
WO-2010015628-A1 PYRAZOLO [5,1-B] OXAZOLE DERIVATIVES AS CRF1 ANTAGONISTS NOVARTIS AG (CH) 2010-02-11 — — WO disclosed
WO-2010015628-A1 PYRAZOLO [5,1-B] OXAZOLE DERIVATIVES AS CRF1 ANTAGONISTS NOVARTIS AG (CH) 2010-02-11 — — WO disclosed
US-20100035874-A1 Organic compounds NOVARTIS AG (CH) 2010-02-11 — — US disclosed
US-20100035874-A1 Organic compounds NOVARTIS AG (CH) 2010-02-11 — — US disclosed
US-20100035874-A1 Organic compounds NOVARTIS AG (CH) 2010-02-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035874-A1 Organic compounds CRH, CRHR1, CRHR2 DPP4 958/4885THRB 369/4885NPC1 1952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.